Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?

Abali, H.; Yavuz, S.; Calikusu, Z.; Seyrek, E.

doi:10.1093/annonc/mdu473

Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?

Abali H., Yavuz S., Calikusu Z., Seyrek E.

ANNALS OF ONCOLOGY, vol.26, no.1, pp.245, 2015 (Journal Indexed in SCI)

Publication Type: Article / Letter
Volume: 26 Issue: 1
Publication Date: 2015
Doi Number: 10.1093/annonc/mdu473
Title of Journal : ANNALS OF ONCOLOGY
Page Numbers: pp.245

Abstract

This letter criticize the design of ACTS-CC trial; patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.